CVSCVS Health Corp.
This is the year CVS has to prove it’s not just surviving but thriving in a sector that’s been anything but kind. The next catalyst is the Q3 2026 Earnings Release on 2026-11-04, where the stock is anchored at $97.21, with a bull target of $105.23 and a bear fallback of $90.19. The market is looking for a clear signal on how the company is navigating the ongoing healthcare cost pressures, pharmacy consolidation, and the lingering effects of the pandemic. If the bull path materializes, it would mean a strong performance that aligns with the company’s long-term strategy of integrating health services and expanding its retail footprint. If the bear path takes hold, it could signal deeper-than-expected challenges in margins or execution. Either way, this event is a test of whether CVS can deliver the kind of results that justify its current valuation and position it for the next phase of growth.
The schedule
- Wed4Nov
The Q3 2026 Earnings Release and Guidance is a key event that will provide insight into CVS's financial performance and future outlook. This event is expected to have a high impact on the stock price due to its significance in the quarterly cycle. The market will be closely watching for details on revenue, profit, and any strategic updates from the company. Investors should be prepared for potential volatility around the time of the release, as it could influence both bullish and bearish sentiment.
- Tue9Feb
- Wed5May
- Wed4Aug
Past
- Wed6May
Actual outcome: Bull · $90.55 at outcome
CVS delivered a strong Q1 earnings beat, with revenues exceeding $100 billion and adjusted EPS of $2.57 topping estimates of $2.21. The stock rallied as the company raised its full-year 2026 guidance, driven by improving medical cost controls and easing subscriber costs within its Aetna insurance division that directly addressed key market concerns.
CVS delivered a strong Q1 earnings beat, with revenues exceeding $100 billion and adjusted EPS of $2.57 topping estimates of $2.21. The stock rallied as the company raised its full-year 2026 guidance, driven by improving medical cost controls and easing subscriber costs within its Aetna insurance division that directly addressed key market concerns.
- Thu16Apr
Actual outcome: Bull · $83.29 at outcome
The Centers for Medicare & Medicaid Services (CMS) finalized the 2027 Medicare Advantage payment rate at a 2.48% net average increase, significantly beating both the 0.09% initial proposal and the 1% Street expectation. This highly favorable rate update delivered the bull-case catalyst by providing much stronger reimbursement visibility for Aetna, though the stock's upward momentum was ultimately tempered by news of a potential strike by CVS distribution center workers.
The Centers for Medicare & Medicaid Services (CMS) finalized the 2027 Medicare Advantage payment rate at a 2.48% net average increase, significantly beating both the 0.09% initial proposal and the 1% Street expectation. This highly favorable rate update delivered the bull-case catalyst by providing much stronger reimbursement visibility for Aetna, though the stock's upward momentum was ultimately tempered by news of a potential strike by CVS distribution center workers.
- Wed25Mar
Actual outcome: Bull · $97.15 at outcome
Despite initial concerns regarding heightened PBM legislative risk under the Trump administration, the proposed regulatory framework proved much less restrictive than anticipated, removing a major overhang on the stock. Furthermore, strong first-quarter earnings and robust forward guidance shifted market focus toward the company's fundamental resilience, driving a massive 34.6% rally well past the bull target.
Despite initial concerns regarding heightened PBM legislative risk under the Trump administration, the proposed regulatory framework proved much less restrictive than anticipated, removing a major overhang on the stock. Furthermore, strong first-quarter earnings and robust forward guidance shifted market focus toward the company's fundamental resilience, driving a massive 34.6% rally well past the bull target.
- Tue10Feb
Actual outcome: Bull · $77.93 at outcome
CVS delivered a strong Q4 2025 beat on both revenue ($105.7B vs $103.6B) and adjusted EPS ($1.09 vs $0.99). While the stock initially slid due to persistent Medicare Advantage cost pressures in Aetna and management only reiterating (rather than raising) the 2026 profit outlook, the market quickly digested the news. Investors ultimately prioritized the robust Q4 performance and strong revenue growth, driving the stock to recover significantly and move toward the bull target.
CVS delivered a strong Q4 2025 beat on both revenue ($105.7B vs $103.6B) and adjusted EPS ($1.09 vs $0.99). While the stock initially slid due to persistent Medicare Advantage cost pressures in Aetna and management only reiterating (rather than raising) the 2026 profit outlook, the market quickly digested the news. Investors ultimately prioritized the robust Q4 performance and strong revenue growth, driving the stock to recover significantly and move toward the bull target.
